

Gary T Ferguson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9577321/publications.pdf>

Version: 2024-02-01

55
papers

7,759
citations

257450

24
h-index

155660

55
g-index

55
all docs

55
docs citations

55
times ranked

5145
citing authors

#	ARTICLE	IF	CITATIONS
1	Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease. <i>New England Journal of Medicine</i> , 2007, 356, 775-789.	27.0	2,963
2	Benralizumab, an anti-interleukin-5 receptor $\hat{\pm}$ monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet</i> , 2016, 388, 2128-2141.	13.7	1,070
3	Effect of Pharmacotherapy on Rate of Decline of Lung Function in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 178, 332-338.	5.6	692
4	Dual bronchodilation with QVA149 <i>versus</i> single bronchodilator therapy: the SHINE study. <i>European Respiratory Journal</i> , 2013, 42, 1484-1494.	6.7	358
5	Tiotropium and olodaterol fixed-dose combination <i>versus</i> mono-components in COPD (GOLD) Tj ETQq1 1 0.784314 rgBT /Overlook 294	6.7	294
6	Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. <i>Respiratory Research</i> , 2009, 10, 59.	3.6	287
7	Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. <i>Lancet Respiratory Medicine</i> , 2018, 6, 747-758.	10.7	254
8	Prevalence and Progression of Osteoporosis in Patients With COPD. <i>Chest</i> , 2009, 136, 1456-1465.	0.8	240
9	Effect of fluticasone propionate/salmeterol (250/50 $\hat{\mu}$ g) or salmeterol (50 $\hat{\mu}$ g) on COPD exacerbations. <i>Respiratory Medicine</i> , 2008, 102, 1099-1108.	2.9	211
10	Effect of Fluticasone Propionate/Salmeterol (250/50) on COPD Exacerbations and Impact on Patient Outcomes. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2009, 6, 320-329.	1.6	154
11	Tiotropium $\hat{\pm}$ Olodaterol shows clinically meaningful improvements in quality of life. <i>Respiratory Medicine</i> , 2015, 109, 1312-1319.	2.9	144
12	Why Does the Lung Hyperinflate?. <i>Proceedings of the American Thoracic Society</i> , 2006, 3, 176-179.	3.5	125
13	Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2017, 5, 568-576.	10.7	99
14	Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD. <i>Chest</i> , 2017, 151, 340-357.	0.8	91
15	Efficacy and safety of olodaterol once daily delivered via Respimat $\hat{\pm}$ in patients with GOLD 2 $\hat{\pm}$ 4 COPD: results from two replicate 48-week studies. <i>International Journal of COPD</i> , 2014, 9, 629.	2.3	68
16	Efficacy of Tiotropium $\hat{\pm}$ Olodaterol in Patients with Chronic Obstructive Pulmonary Disease by Initial Disease Severity and Treatment Intensity: A Post Hoc Analysis. <i>Advances in Therapy</i> , 2015, 32, 523-536.	2.9	44
17	Severity of COPD at initial spirometry-confirmed diagnosis: data from medical charts and administrative claims. <i>International Journal of COPD</i> , 2011, 6, 573.	2.3	40
18	Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE (Revealing the) Tj ETQq0 0 0 rgBT /Overlook 10 Tf 5	0.0	0

#	ARTICLE	IF	CITATIONS
19	Effects of tiotropium+olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies. <i>Respiratory Research</i> , 2016, 17, 73.	3.6	37
20	Efficacy and safety of glycopyrrolate/eFlow® CS (nebulized glycopyrrolate) in moderate-to-very-severe COPD: Results from the glycopyrrolate for obstructive lung disease via electronic nebulizer (GOLDEN) 3 and 4 randomized controlled trials. <i>Respiratory Medicine</i> , 2017, 132, 238-250.	2.9	36
21	One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2-4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2015, 12, 484-493.	1.6	29
22	β ₂ -Blockers in COPD. <i>Chest</i> , 2018, 153, 1315-1325.	0.8	29
23	A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6µg and 160/18/9.6µg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol. <i>Respiratory Medicine</i> , 2019, 158, 59-66.		27
24	Real-World Evidence: Bridging Gaps in Evidence to Guide Payer Decisions. <i>PharmacoEconomics - Open</i> , 2021, 5, 3-11.	1.8	27
25	Co-suspension delivery technology in pressurized metered-dose inhalers for multi-drug dosing in the treatment of respiratory diseases. <i>Respiratory Medicine</i> , 2018, 134, 16-23.	2.9	26
26	Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials. <i>Respiratory Research</i> , 2020, 21, 131.	3.6	25
27	Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies. <i>Npj Primary Care Respiratory Medicine</i> , 2017, 27, 7.	2.6	24
28	Assessment of an accessorized pre-filled syringe for home-administered benralizumab in severe asthma. <i>Journal of Asthma and Allergy</i> , 2018, Volume 11, 63-72.	3.4	22
29	A Randomized, Double-Blind, Double-Dummy Study of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Relative to Umeclidinium/Vilanterol Dry Powder Inhaler in COPD. <i>Advances in Therapy</i> , 2019, 36, 2434-2449.	2.9	22
30	COPD patient satisfaction with ipratropium bromide/albuterol delivered via Respimat: a randomized, controlled study. <i>International Journal of COPD</i> , 2013, 8, 139.	2.3	20
31	<i>In Vitro</i> Characterization of the eFlow Closed System Nebulizer with Glycopyrrolate Inhalation Solution. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2018, 31, 162-169.	1.4	20
32	Long-term safety of glycopyrrolate/eFlow® CS in moderate-to-very-severe COPD: Results from the Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer (GOLDEN) 5 randomized study. <i>Respiratory Medicine</i> , 2017, 132, 251-260.	2.9	19
33	Bone and ocular safety of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a 52-week randomized study. <i>Respiratory Research</i> , 2019, 20, 167.	3.6	18
34	Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO and OTEMTO studies: a subgroup analysis by age. <i>International Journal of COPD</i> , 2016, Volume 11, 2701-2710.	2.3	17
35	Safety of tiotropium/olodaterol in chronic obstructive pulmonary disease: pooled analysis of three large, 52-week, randomized clinical trials. <i>Respiratory Medicine</i> , 2018, 143, 67-73.	2.9	16
36	Budesonide/formoterol MDI with co-suspension delivery technology in COPD: the TELOS study. <i>European Respiratory Journal</i> , 2018, 52, 1801334.	6.7	16

#	ARTICLE	IF	CITATIONS
37	Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β_2 -Agonist (ICS/LAMA/LABA) Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis. <i>Advances in Therapy</i> , 2020, 37, 2956-2975.	2.9	15
38	Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol Fumarate versus Other Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis. <i>Advances in Therapy</i> , 2021, 38, 3089-3112.	2.9	15
39	Maintenance pharmacotherapy of mild and moderate COPD: What is the Evidence?. <i>Respiratory Medicine</i> , 2011, 105, 1268-1274.	2.9	14
40	<p>Single-Use Autoinjector Functionality And Reliability For At-Home Administration Of Benralizumab For Patients With Severe Asthma: GRECO Trial Results</p>. <i>Journal of Asthma and Allergy</i> , 2019, Volume 12, 363-373.	3.4	14
41	<p>Long-Term Safety and Efficacy of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD</p>. <i>International Journal of COPD</i> , 2019, Volume 14, 2993-3002.	2.3	12
42	<p>Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD: A Subgroup Analysis of the KRONOS Study</p>. <i>International Journal of COPD</i> , 2019, Volume 14, 2979-2991.	2.3	12
43	Benefits of budesonide/glycopyrrolate/formoterol fumarate (BGF) on symptoms and quality of life in patients with COPD in the ETHOS trial. <i>Respiratory Medicine</i> , 2021, 185, 106509.	2.9	12
44	Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Exacerbation Outcomes in Patients with COPD without a Recent Exacerbation History: A Subgroup Analysis of KRONOS. <i>International Journal of COPD</i> , 2021, Volume 16, 179-189.	2.3	9
45	Effect of tiotropium on spontaneous expiratory flowâ€™volume curves during exercise in GOLD 1-2 COPD. <i>Respiratory Physiology and Neurobiology</i> , 2018, 251, 8-15.	1.6	8
46	Effects of baseline symptom burden on treatment response in COPD. <i>International Journal of COPD</i> , 2019, Volume 14, 181-194.	2.3	8
47	Benefits of Tiotropium/Olodaterol Compared with Tiotropium in Patients with COPD Receiving only LAMA at Baseline: Pooled Analysis of the TONADOÂ® and OTEMTOÂ® Studies. <i>Advances in Therapy</i> , 2020, 37, 3485-3499.	2.9	7
48	Cardiovascular safety profile of a fixed-dose combination of glycopyrrolate and formoterol fumarate delivered via metered dose inhaler using co-suspension delivery technology. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018, 49, 67-74.	2.6	6
49	An overview of glycopyrrolate/eFlowÂ® CS in COPD. <i>Expert Review of Respiratory Medicine</i> , 2018, 12, 447-459.	2.5	5
50	Satisfaction with the Use of eFlow Closed-System Nebulizer in Patients with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: Findings from a Long-Term Safety Study. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2019, 32, 24-33.	1.4	5
51	TRONARTO: A Randomized, Placebo-Controlled Study of Tiotropium/Olodaterol Delivered via Soft Mist Inhaler in COPD Patients Stratified by Peak Inspiratory Flow. <i>International Journal of COPD</i> , 2021, Volume 16, 2455-2465.	2.3	4
52	Health-Related Quality of Life Improvements in Moderate to Very Severe Chronic Obstructive Pulmonary Disease Patients on Nebulized Glycopyrrolate: Evidence from the GOLDEN Studies. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2018, 5, 193-207.	0.7	3
53	Clinical implications of the tiotropium/olodaterol inhaler for patients with chronic obstructive pulmonary disease. <i>Postgraduate Medicine</i> , 2018, 130, 515-522.	2.0	2
54	<p>Unreported and Overlooked: A Post Hoc Analysis of COPD Symptom-Related Attacks from the RISE Study</p>. <i>International Journal of COPD</i> , 2020, Volume 15, 3123-3134.	2.3	2

#	ARTICLE	IF	CITATIONS
55	Long-term safety of tiotropium/olodaterol in older patients with moderate-to-very-severe COPD in the TONADO® studies. <i>Npj Primary Care Respiratory Medicine</i> , 2020, 30, 53.	2.6	2